Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (rha) (virus souche a/michigan/45/2015)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015), haemagglutininum influenzae a (h3n2) (rha) (virus souche a/singapore/infimh-16-0019/2016)-like: reassortant virus ivr-186 derived form a/singapore/infimh-16-0019/2016), haemagglutininum influenzae b (rha) (virus souche b/phuket/3073/2013-like: reassortant virus b/phuket/3073/2013 (yamagata lineage)) - solution injectable dans une seringue pré-remplie - haemagglutininum influenzae a (h1n1) (adnr) (virus souche a/michigan/45/2015)-like: reassortant virus nymc x-275 derived from a/michigan/45/2015) 45 µg, haemagglutininum influenzae a (h3n2) (adnr) (virus souche a/singapore/infimh-16-0019/2016)-like: reassortant virus ivr-186 derived form a/singapore/infimh-16-0019/2016) 45 µg, haemagglutininum influenzae b (adnr) (virus souche b/phuket/3073/2013-like: reassortant virus b/phuket/3073/2013 (yamagata lineage)) 45 µg, haemagglutininum influenzae b (adnr) (virus souche b/colorado/6/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 45 µg, natrii dihydrogenophosphas monohydricus, dinatrii phosphas dodecahydricus, natrii chloridum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml corresp. natrium 1.84 mg, residui: octoxinolum-9. - immunisation active contre l'influenza, dès 18 ans - impfstoffe

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)pdm09-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/2570/2019 (h1n1)-like: reassortant virus ivr-215 derived from a/victoria/2570/2019) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021) 60 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - impfstoffe

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)pdm09-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus ivr-228 derived from a/darwin/9/2021) 15 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: b/michigan/01/2021, wilde type (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: b/phuket/3073/2013, wilde type (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)-like: reassortant virus ivr-238 derived from a/victoria/4897/2022), haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021), haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) - suspension injectable en seringue préremplie - haemagglutininum influenzae a (h1n1) (virus souche a/victoria/4897/2022 (h1n1)-like: reassortant virus ivr-238 derived from a/victoria/4897/2022) 60 µg, haemagglutininum influenzae a (h3n2) (virus souche a/darwin/9/2021 (h3n2)-like: reassortant virus san-010 derived from a/darwin/9/2021) 60 µg, haemagglutininum influenzae b (virus souche b/austria/1359417/2021-like: derived from b/michigan/01/2021 (victoria lineage)(wild type)) 60 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013 (yamagata lineage) (wild type)) 60 µg, natrii chloridum, dinatrii phosphas, natrii dihydrogenophosphas anhydricus, octoxinolum-9, aqua ad iniectabile q.s. ad suspensionem pro 0.7 ml corresp. natrium 2.72 mg. - immunisation active contre l'influenza, dès 65 ans - impfstoffe

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus-souche a/hongkong/4801/2014 (h3n2)-like: reassortanten virus nymc x-263b), haemagglutininum influenzae b (virus-souche b/brisbane/60/2008) - injizierbare suspension - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus-souche a/hongkong/4801/2014 (h3n2)-like: reassortanten virus nymc x-263b) 15 µg, haemagglutininum influenzae b (virus-souche b/brisbane/60/2008) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, der rest: formaldehydum max. 100 µg, octoxinolum-9 max. 500 µg, ovalbuminum max. 0,05 µg, kunststoff nein, neomycinum nichts, wasser zu iniectabilia q.s. zu der suspension 0,5 ml. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus-souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortanten virus ivr-186), haemagglutininum influenzae b (virus-souche b/colorado/06/2017-wie: reassortanten virus nymc bx-69a, abgeleitet von b/maryland/15/2016 (victoria-linie)) - suspension zur injektion in einer fertigspritze - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016 (victoria lineage)) 15 µg, haemagglutininum influenzae b (virus souche b/phuket/3073/2013-like: reassortant virus wild type derived from b/phuket/3073/2013 (yamagata lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml, residui: formaldehydum, octoxinolum-9, neomycinum, ovalbuminum. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - haemagglutininum influenzae a (h1n1) (virus-souche a/michigan/45/2015 (h1n1)-like: reassortanten virus nymc x-275), haemagglutininum influenzae a (h3n2) (virus-souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortanten virus ivr-186), haemagglutininum influenzae b (virus-souche b/colorado/06/2017-wie: reassortanten virus nymc bx-69a, abgeleitet von b/maryland/15/2016) - injizierbare suspension - haemagglutininum influenzae a (h1n1) (virus souche a/michigan/45/2015 (h1n1)-like: reassortant virus nymc x-275) 15 µg, haemagglutininum influenzae a (h3n2) (virus souche a/singapore/infimh-16-0019/2016 (h3n2)-like: reassortant virus ivr-186) 15 µg, haemagglutininum influenzae b (virus souche b/colorado/06/2017-like: reassortant virus nymc bx-69a derived from b/maryland/15/2016) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, residui: formaldehydum max. 30 µg, octoxinolum-9 max. 200 µg, neomycinum max. 7.5 pg, ovalbuminum max. 50 ng, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen influenza, ab dem 6. monat - impfstoffe

Šveice - vācu - OFAG-BLW (Bundesamt für Landwirtschaft)

schneiter agro ag - schwefel - wgwasserdispergierbares granulat - 80 % ; - akarizid ; fungizid ;

Vācija - vācu - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

pharma resources dr. schluttig gmbh (8056069) - sulbactam-natrium; ampicillin-natrium - pulver zur herstellung einer injektionslösung - sulbactam-natrium (23678) 273,5 milligramm; ampicillin-natrium (02070) 532 milligramm